Study S000952

Study on the Effect of Metformin vs Metformin Combined With GLP-1 RA (Exenatide) on Overweight/Obese Patients With Polycystic Ovary Syndrome (PCOS)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04029272
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: UNKNOWN
Enrollment: 80
Start: 2019-07-20
Primary completion: 2020-02-28
Lead sponsor: Peking Union Medical College Hospital
Conditions: Polycystic Ovary Syndrome
Interventions: DRUG:Metformin; DRUG:Exenatide 2 MG
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in body weight [Patient's body weight was measured at the baseline and after 12 weeks of clinical trial]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016671	Combined metformin and exenatide versus only metformin treatments in polycystic ovary syndrome with abdominal obesity and network pharmacology of gene expression: evidence from a randomized clinical trial. Xuesong D, Therapeutic advances in endocrinology and metabolism	2025	Randomized trial	PMID 40843067 DOI	cites ClinicalTrials.gov:NCT04029272; registry reference DERIVED:40843067
R0011463	Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. Ma RL, Chinese medical journal	2021	Randomized trial	PMID 34732660 DOI	cites ClinicalTrials.gov:NCT04029272; registry reference DERIVED:34732660